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Effects of dopamine D2/D3 receptor antagonism on human
planning and spatial working memory
M Naef1, U Müller2,3, A Linssen4, L Clark2,5, TW Robbins2 and C Eisenegger6,{
Psychopharmacological studies in humans suggest important roles for dopamine (DA) D2 receptors in human executive functions,
such as cognitive planning and spatial working memory (SWM). However, studies that investigate an impairment of such functions
using the selective DA D2/3 receptor antagonist sulpiride have yielded inconsistent results, perhaps because relatively low doses
were used. We believe we report for the ﬁrst time, the effects of a higher (800 mg p.o.) single dose of sulpiride as well as of genetic
variation in the DA receptor D2 gene (DA receptor D2 Taq1A polymorphism), on planning and working memory. With 78 healthy
male volunteers, we apply a between-groups, placebo-controlled design. We measure outcomes in the difﬁcult versions of the
Cambridge Neuropsychological Test Automated Battery One-Touch Stockings of Cambridge and the self-ordered SWM task.
Volunteers in the sulpiride group showed signiﬁcant impairments in planning accuracy and, for the more difﬁcult problems, in
SWM. Sulpiride administration speeded response latencies in the planning task on the most difﬁcult problems. Volunteers with at
least one copy of the minor allele (A1+) of the DA receptor D2 Taq1A polymorphism showed better SWM capacity, regardless of
whether they received sulpiride or placebo. There were no effects on blood pressure, heart rate or subjective sedation. In sum, a
higher single dose of sulpiride impairs SWM and executive planning functions, in a manner independent of the DA receptor D2
Taq1A polymorphism.
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INTRODUCTION
The role of the dopaminergic system in modulating cognitive
functions within the prefrontal cortex and striatum is well
established.1–4 The concept of fronto-striatal circuitry emphasizes
the functional inter-relationship between the prefrontal cortex
and the striatum, with the latter inﬂuencing cortical higher-order
cognitive functions and vice versa.5,6 Cognitive functions such as
planning and working memory depend critically on dopamine
signalling within this circuit. This has been shown by psycho-
pharmacological drug challenges, genetic studies and research on
diseases that affect fronto-striatal dopamine (DA) levels.7–13
Although DA D2 receptors occur at lower density in the
prefrontal cortex than DA D1 receptors, D2 receptors are
nevertheless implicated in planning and working memory. For
instance, administration of the DA D2 agonist bromocriptine
enhanced performance on a delayed-response working memory
task, whereas low doses of the DA D2 antagonist haloperidol
impaired performance.14,15 Furthermore, a relationship between
striatal DA D2 receptor density and planning accuracy was observed
in Huntington’s disease patients,16,17 suggesting that the dopami-
nergic system exerts part of its modulatory role on planning and
working memory performance via the DA D2 receptor.
The DA D2/D3 antagonist sulpiride has been investigated using
relatively low doses of 200 and 400 mg.7 Sulpiride was found to
cause a dose-dependent impairment in short-term spatial location
memory, as well as impaired planning in the most difﬁcult stages
of the one-touch Tower of London task. In a subsequent
pharmaco-PET study, 400 mg of sulpiride had no effect on spatial
working memory (SWM), and paradoxically improved planning
performance.8 This effect was paralleled by a decrease in regional
cerebral blood ﬂow in the caudate.8 In another study18 using the
self-ordered SWM task from the Cambridge Neuropsychological
Test Automated Battery (CANTAB), 400 mg of sulpiride did not
affect performance, but puzzlingly, others even reported
improved accuracy of working memory following the same dose
of sulpiride.19
One account for these discrepant results is that perhaps 400 mg
sulpiride does not result in sufﬁcient occupancy of postsynaptic
DA D2 receptors to reliably impair executive functions. Further-
more, it has been observed that low doses of amisulpride (similar
to sulpiride, both being selective for DA D2/3 receptors) exert a
greater functional blockade of cortical and limbic, rather than
striatal, DA D2 receptors.20,21 DA release may even increase in these
regions as a consequence of presynaptic DA D2 autoreceptor
blockade.22 Overall, the causal role of postsynaptic DA D2 receptors
in planning and SWM in healthy humans remains elusive.
To achieve a sufﬁcient blockade of postsynaptic DA D2
receptors within the fronto-striatal circuitry, higher doses of
sulpiride may have to be administered. Previous studies have
shown that a single dose of 400 mg sulpiride occupies roughly
30% of striatal DA D2 receptors,23 whereas an 800 mg dose results
in roughly 60% occupancy levels, yet still without causing
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demonstrable side effects in healthy volunteers.24,25 We therefore
used a dose of 800 mg p.o. in the present study.
Finally, although sulpiride does not possess signiﬁcant binding
to α-adrenergic, histaminergic or serotoninergic receptors, it
nevertheless does not discriminate between the DA D2 and D3
receptors. As the anatomical distribution of these two receptors is
only partially overlapping, a pharmacogenetic study design24,26–28
may enable more speciﬁc inferences to be drawn regarding the
role of the DA receptor D2 in planning and working memory
performance. A relevant candidate genetic variation in this
context is the DA D2 receptor Taq1A polymorphism, as its minor
A1 allele has been associated speciﬁcally with a reduction in
striatal DA receptor D2 density of up to 30 percent.29–33 Based on
this evidence, one might expect A1+ volunteers to be dispro-
portionately sensitive to DA receptor D2 antagonism in terms of
behavioural impairments in planning and working memory
performance.
We hypothesize that a single dose of 800 mg sulpiride
administered p.o. to healthy volunteers induces impairments in
working memory and planning performance, compared with
placebo. We also predict this impairment to be most pronounced
in volunteers carrying the minor A1+ allele of the DA receptor D2
Taq1A polymorphism.
MATERIALS AND METHODS
Volunteers
Seventy-eight healthy men aged between 19 and 44 years (mean= 32.1)
participated. All were recruited from Cambridge BioResource, a large
community-based panel of volunteers for research linking genotype to
phenotype (http://www.cambridgebioresource.org.uk). All volunteers are
right-handed European or North American Caucasians. Volunteers were
stratiﬁed based on their DA receptor D2 Taq1A genotype, with one group
consisting of individuals carrying one or two copies of the A1 allele and the
other group consisting of A2 allele homozygotes. All volunteers were task-
naive and none had participated in previous psychoactive drug studies.
Volunteers’ mental and physical health was screened before genotyping
using a detailed medical history questionnaire used by Cambridge
BioResource. This revealed no history of neurological disease or psychiatric
disorders. In addition, the psychiatrist on site performed another
structured interview, conﬁrming that volunteers had no signiﬁcant general
psychiatric, medical or neurological disorder and were not currently taking
any prescription medicine, nor drugs of abuse. All volunteers were
required to perform an alcohol test on arrival at the lab using a
commercially available breath alcohol analyser. This conﬁrmed that no
volunteer had consumed alcohol on the study day.
The study was performed in accordance with the Declaration of Helsinki
and approved by the National Research Ethics Committee of Hertfordshire
(11/EE/0111). All volunteers were included in the study only after having
provided written informed consent. For three volunteers, data collection
was unsuccessful: one felt uncomfortable in the testing room (sulpiride
group A1− ), and two non-native English-speaking volunteers (placebo
group A1− , sulpiride group A1− ) did not sufﬁciently understand the
instructions for the CANTAB tasks. In addition to the working memory and
planning tasks reported here, volunteers also completed an incentivized
reinforcement learning task24 and incentivised social interaction tasks
(assessing negative and positive reciprocity). The working memory and
planning tasks reported in this paper were not incentivized; volunteers
received a ﬂat fee of £50 for participation in the study, plus any additional
earnings from the incentivized tasks. Verbal intelligence quotient (IQ)
estimates were calculated for all volunteers (National Adult Reading Test;34
mean= 119.8 ± 7.33; range= 101–129). A technical fault led to the omission
of one further volunteer on the SWM task (sulpiride group A1+).
Experimental design
We used a between-subject, double-blind, placebo-controlled design,
where 78 volunteers were randomized to receive either a single oral
dose of 800 mg sulpiride or placebo. The volunteers were stratiﬁed based
on their DA receptor D2 Taq1A genotype, yielding the following
four groups: A1+ volunteers who were administered sulpiride (n= 21)
and A1+ volunteers who were administered placebo (n= 17); as well as
A1− volunteers who were administered sulpiride (n= 19) and A1−
volunteers who were administered placebo (n= 21). There were no
differences across the four groups with regard to age (P-values40.49),
body mass index (P-values40.24) or IQ (P-values40.42).
Procedure
On the study day, volunteers arrived at the lab between 0830 h and
1000 h. At the start, volunteers completed two questionnaires for assessing
current mood (visual analogue scale). Then, pulse rate and blood pressure
were measured and blood samples (10 ml) were taken. All volunteers then
received either a sulpiride or placebo capsule, which was administered
orally. After ingesting the pill, volunteers passed a waiting period in
individual rooms. While waiting, volunteers were allowed to read
newspapers. In line with a previous study,8 the planning task was
administered 3 h after capsule ingestion to coincide with the time window
of maximal sulpiride effects. Before the task started, volunteers had to
complete a comprehensive side-effect questionnaire,35 current mood,
blood pressure and pulse rate were measured and a second blood sample
was taken (Supplementary Table 1). The SWM and one-touch stockings of
Cambridge (OTSOC) tasks were presented on computers and responses
were registered via touch-sensitive screens. At the end of the experiment,
volunteers were asked to guess whether they had received the sulpiride or
the placebo pill (Supplementary Table 1).
CANTAB SWM task
The SWM is a self-ordered search task, which requires volunteers to search
through a spatial array of 4, 6, 8, 10 or 12 coloured squares (boxes) for a
‘token’ that is hidden in one of the boxes. Volunteers touch a box to reveal
whether the token is in the box or not. Once a token is found, the search
starts again, but is no longer completely random. Volunteers know that no
token will be hidden in a box where a token was previously hidden. Thus,
each round fewer boxes are possible candidates; each round, volunteers
have to remember more boxes that are no longer ‘in the game’. In this test,
volunteers have to use mnemonic information to work towards a goal.
Between-search errors are ‘forgetting’ errors committed when a box that
has previously been successful is revisited during a subsequent search.
Within-search errors entail revisiting a box within a search, that is, the
number of times a volunteer revisits a box already found to be empty
during the same search. An efﬁcient strategy for this problem is to start
each search sequence with the same box. Our strategy score is quantiﬁed
as the number of times the volunteer starts a search sequence from a
different box (thus a higher strategy score represents inefﬁcient strategy
use). The strategy score is typically correlated with working memory errors,
but strategy is speciﬁcally impaired in patients with frontal (but not
temporal) lobe injury.36 Volunteers did two practice searches with three
boxes each. The practice searches were completed immediately before the
main SWM task, and successful solving of these practice searches was a
requirement for progressing onto the main test. The main task consisted of
ﬁfteen problems in total, three for each of the ﬁve difﬁculty levels.
CANTAB OTSOC task
We investigated planning using a modiﬁed version of the Tower of London
task, the OTSOC from the CANTAB (Cambridge Cognition, http://www.
camcog.com). In this modiﬁed version of the task, volunteers are required
to determine the minimum number of moves needed to solve the problem
without actually moving any of the balls. This modiﬁcation forces
volunteers to plan the solution in full before initiating a response. This
ensures actual planning and enables an improved investigation of the
speciﬁc relation between the time to initiate the ﬁrst response (response
latency), the problem difﬁculty and the number of attempts to solve the
problem (accuracy).
In the OTSOC, volunteers were ﬁrst presented with two displays on a
computer screen, each showing three coloured balls arranged within three
stockings. The challenge was to match the lower to the upper display and
to achieve this with the least possible number of moves. The difﬁculty
varied from one to six moves needed to solve a problem. Volunteers were
not required or even able to physically move the balls to replicate the
upper display. They just had to select the minimum number of moves
needed from a list of seven possibilities displayed at the bottom of the
screen. They were allowed to take as many attempts as needed to solve
the problem. The number of attempts to solve the problem (accuracy) and
the time taken to initiate the ﬁrst response (response latency) were
recorded. To conﬁrm that volunteers understood the instructions, they had
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to successfully complete four practice trials immediately before the main
OTSOC task started. The main task consisted of four problems for each of
the six difﬁculty levels, resulting in twenty-four problems in total.
Prolactin level assessment
Plasma prolactin level elevation is considered to be an indicator of
postsynaptic dopamine receptor antagonism.37,38 Postsynaptic dopamine
blockade is predicted to elevate prolactin levels at the second time point,
3 h after capsule ingestion.39,40 The prolactin level was measured using a
commercial immunoradiometric assay (MP Biomedicals, Santa Ana, CA,
USA). The intra- and inter-assay coefﬁcients of variation were 4.2% and
8.2%, respectively, and the limit of detection was 0.5 ng ml− 1.24
Visual analogue scales and side-effects questionnaire
The visual analogue scale41 was used to assess volunteers’ current mood
state at baseline and 3 h after sulpiride/placebo administration. The
original visual analogue scale contains 16 scales. In the present study, we
investigated alertness, calmness and contentedness.
Side effects were recorded using a drug effects questionnaire
(neurovegetative list)35 3 h after sulpiride/placebo administration.
Statistical analysis
Statistical analysis was performed using the software package STATA.
Differences across groups concerning age, body mass index, general IQ
and verbal IQ were analysed using t-tests. Concerning the control variables
current mood, side effects, blood pressure, pulse rate and prolactin level,
we used nonparametric tests such as the Mann–Whitney and the Wilcoxon
signed-rank test.
To calculate the standard errors used in the ﬁgures, we ran ordinary least
squares regressions with the variable on the vertical axis as dependent
variable and the variable on the horizontal axis as explanatory variable. We
ran such a regression for each subgroup we report in the ﬁgures. To take
into account the repeated measurement, standard errors were clustered
on individual level. The clustered standard errors are also robust to some
minor misspeciﬁcations such as minor problems about normality,
heteroscedasticity or some observations that exhibit large residuals,
leverage or inﬂuence.
To analyse the effects of sulpiride and genotype on OTSOC and SWM
variables of interest (including the practice trials), we conducted a
repeated-measures analysis of variance (ANOVA), with task difﬁculty level
as the within-subject factor and sulpiride treatment and genotype as
between-subject factors, as well as all interactions between these variables.
In Supplementary Tables 2 and 3, we report the full results for the four
ANOVAs conducted, whereas in the main text we do not always report all
the variables in detail.
To assess the relationship between accuracy and response latency in
OTSOC, we used ordinary least square regressions with accuracy as
dependent variable and response latency, sulpiride and their interaction as
explanatory variables. In Supplementary Table 4, we report the full results
for the three regressions conducted. We have excluded two outliers in the
regression regarding the relationship between accuracy and response
latency, and they are labelled in Figure 4.
To normalize response latency distribution, the data were log-
transformed and divided by 1000.42 Signiﬁcant differences are reported
as Po0.05. Results do not change qualitatively if IQ is included as a control
variable.
RESULTS
SWM task
Figure 1a shows that volunteers in the sulpiride group made more
between-search errors than volunteers in the placebo group, but
only in the more difﬁcult problems. An ANOVA conﬁrmed the
signiﬁcant interaction effect of drug condition with level of
difﬁculty on between-search errors (F(4,1020) = 2.66, P= 0.031,
η2 = 0.01). The main effect of sulpiride was nonsigniﬁcant (F
(1,70) = 2.15, P = 0.147, η2 = 0.03). Post hoc tests conﬁrmed that the
sulpiride effects in the difﬁcult 10-box and 12-box problems were
signiﬁcantly larger than the sulpiride effect in the easiest four-box
problems (10-box; P= 0.022; 12-box: P= 0.031). The sulpiride
group did not differ signiﬁcantly in their strategy scores from
the placebo group (F(1,70) = 0.63, P= 0.431) nor was there an
interaction effect of drug condition with the task difﬁculty level (F
(4,280) = 0.40, P= 0.807; Figure 1b). Therefore, the sulpiride effect
on between-search errors cannot be explained by more frequent
use of an inefﬁcient strategy.
Considering the effects of the DA receptor D2 Taq1A genotype
(see Figures 2a and b), the A1− volunteers across both drug
conditions made fewer between-search errors in the difﬁcult
problems than the A1+ volunteers. In the ANOVA, this was
conﬁrmed with a signiﬁcant interaction effect of genotype with
the level of difﬁculty on between-search errors (F(4,1020) = 2.55,
P= 0.038, η2 = 0.01). Post hoc tests conﬁrmed that the genotype
effects in the difﬁcult 12- and 10-box problems were signiﬁcantly
larger than the genotype effect in the easiest four-box problems
(10-box; P= 0.069; 12-box: P= 0.011). The main effect of genotype
was nonsigniﬁcant (F(1,70) = 2.79, P= 0.099, η2 = 0.04), and there
was no signiﬁcant interaction of genotype with drug condition (F
(1,70) = 0.13, P= 0.720). For strategy scores (Figures 2c and d), the
main effect of genotype was not signiﬁcant (F(1,70) = 0.39,
P= 0.535), nor the interactions of genotype with difﬁculty level
(F(4,280) = 0.65, P= 0.630) or drug condition (F(1,70) = 0.60,
P= 0.441). Therefore, it seems that the difference in between-
search errors between the A1+ and A1− carriers cannot be
explained by a difference in the extent of using an inefﬁcient
strategy. We do ﬁnd, however, a signiﬁcant three-way interaction
of genotype with sulpiride and task difﬁculty level on the strategy
measure (F(4,280) = 2.48, P= 0.044, η2 = 0.03). This effect is driven
by A1+ volunteers who appear to respond differently to sulpiride
in easier compared with the more difﬁcult problems. This needs to
be interpreted cautiously as we are underpowered for analysing
mere genotype–behaviour associations (that is, 16–20 observa-
tions for each of the four groups).
We also tested whether sulpiride had any effect on the training
process of the SWM task. We ﬁnd no signiﬁcant difference
between the sulpiride and the placebo group in performance in
the two practice trials (P-values40.21). Together with the above
result that there is no difference between the sulpiride and
placebo group in the easy searches in the main task, this indicates
that sulpiride did not affect the training process of the task.
OTSOC measures
In the OTSOC task, volunteers in the sulpiride group required more
attempts to correctly solve the task than volunteers in the placebo
group (Figure 3a). In other words, the accuracy of decisions was
lower in the sulpiride compared with the placebo group, which
was conﬁrmed by an ANOVA (F(1,71) = 5.09, P= 0.027, η2 = 0.07).
The sulpiride effect on accuracy was highest for the two most
difﬁcult problems, though the interaction of task difﬁculty level
with sulpiride was not signiﬁcant (F(5,1705) = 1.71, P= 0.129). With
Figure 1. Effects of sulpiride (800 mg) on the number of between-
search errors (a) and relative use of the inefﬁcient strategy against
task difﬁculty level (b) in the spatial working memory (SWM) task.
Plotted are means± error bars of two standard errors (corrected for
repeated observations).
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regards to response latencies, we analysed the response latency of
the ﬁrst response. As can be seen from Figure 3b, there was no
main effect of sulpiride on response latencies (F(1,71) = 0.67,
P= 0.416). There was a signiﬁcant interaction between drug
condition and task difﬁculty on planning latency (F(5,1705) = 3.43,
P= 0.004, η2 = 0.01), such that the response latency was signiﬁ-
cantly shorter on sulpiride compared with placebo for the most
difﬁcult problems. A post hoc test conﬁrmed that the sulpiride
effect on response latency was larger in the most difﬁcult
problems compared with the easiest problems (P= 0.001).
To further specify the nature of this association, we tested the
relationship between response latencies and accuracy for easier
and more difﬁcult problems separately. A negative relationship
between speed and accuracy (represented by our measures of
their opposites, response latency and mistakes) can be interpreted
as a speed-accuracy trade-off. In other words, spend more time
thinking about it to make fewer mistakes, or make a quick
response at the cost of possibly being mistaken. To test this
relationship, we use an ordinary least square regression with mean
number of moves above minimum as the dependent variable and
response latency, sulpiride and their interaction as explanatory
variables. In the easier problems (minimum possible moves from 1
to 4), we found that the relationship between speed and accuracy
was signiﬁcantly positive in the placebo group (βlatency = 0.10,
P= 0.045) and also positive but insigniﬁcant in the sulpiride group
(βlatency = 0.08, P= 0.410). The interaction between sulpiride and
response latency was not signiﬁcant either (βlatency sulpiride =− 0.02,
P= 0.834). The lack of a negative relationship between speed and
accuracy indicates that there is no speed-accuracy trade-off in
easy problems (Figure 4a). However, for the more difﬁcult
problems (ﬁve to six minimum possible moves), there was a
negative relation between speed and accuracy in both the
sulpiride (six moves: βlatency =− 0.72, Po0.001; ﬁve moves: βlatency
=− 0.16, P = 0.279) and the placebo group (six moves: βlatency =
− 0.17, P= 0.094; ﬁve moves: βlatency =− 0.27, P= 0.089), which is
consistent with a speed-accuracy trade-off (Figure 4b). The trade-
off is most pronounced in the six-move problems and weaker in
the ﬁve-move problems. Possibly, it takes a certain degree of
complexity or difﬁculty for a speed-accuracy trade-off to emerge.
Interestingly, in the hardest problems (six moves) the speed-
accuracy trade-off was signiﬁcantly larger in the sulpiride
compared with the placebo group (βlatency × sulpiride =− 0.55,
Po0.001). The larger speed-accuracy trade-off in the sulpiride
group compared with the placebo group is driven by more fast,
imprecise responses (rather than long response latencies and few
mistakes) in the sulpiride group (Figure 4b). This suggests that
sulpiride alters the speed-accuracy trade-off in planning towards
impulsive, less accurate responses. This needs to be interpreted
with caution as the number of observations in this analysis is
smaller than in the main analyses reported above (that is, it is
based on 74 volunteers each doing four six-move problems).
Concerning DA receptor D2 Taq1A genotype (Figure 5), there
was neither a signiﬁcant main effect of genotype (F(1,71) = 0.01,
Figure 2. The effects of the dopamine (DA) receptor D2 Taq1A genotype on between-error searches (a and b) and relative use of the
inefﬁcient strategy against task difﬁculty level (c and d) in the spatial working memory (SWM) task. The left column (a and c) shows theses
effects for the placebo group and the right column (b and d) for the sulpiride group only. Plotted are means± error bars of two standard
errors (corrected for repeated observations).
Figure 3. Sulpiride (800 mg) effects on the mean number of moves
required to correctly solve the task (accuracy) (a) and the mean log
response latency taken for the ﬁrst response to be made against task
difﬁculty level (b) in the OTSOC task. Plotted are means± error bars
of 2 standard errors (corrected for repeated observations). OTSOC,
one-touch stockings of Cambridge.
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P= 0.941), nor a signiﬁcant interaction with task difﬁculty
(F(5,1705) = 1.84, P= 0.103) or drug condition (F(1,71) = 0.85,
P= 0.361) on accuracy. Also, there was neither a signiﬁcant main
effect of genotype nor signiﬁcant interactions of genotype with
drug condition and task difﬁculty on response latency measures
(P-values40.708).
We also tested whether sulpiride had any effect on the training
process of the OTSOC task. We ﬁnd no signiﬁcant difference in the
accuracy of the decisions in the four practice trials between the
sulpiride and the placebo group (P-values40.19). Together with
the above result that there is no difference between the sulpiride
and placebo group in the one- and two-move problems in the
main task, this is strong evidence that sulpiride did not affect the
training process of the task.
Prolactin secretion and side effects
Results regarding changes in prolactin levels, heart rate and blood
pressure, as well as self-reported measures of sedation are
outlined in the Supplementary Materials and methods as well as
Supplementary Table 1.
DISCUSSION
We found that a high single dose of 800 mg of the selective DA
receptor D2/D3 antagonist sulpiride led to signiﬁcant impairments
in planning accuracy on the OTSOC task, and, for the more difﬁcult
problems, on SWM in the SWM task (with no signiﬁcant effect on
the strategy measure). Sulpiride did not affect sensorimotor
functions, as measured by response latencies in the easy problems
of the OTSOC, but it speeded response latencies on the most
difﬁcult problems. We also observed signiﬁcant modulatory effects
of the DA receptor D2 Taq1A polymorphism on SWM, but not on
planning. Sulpiride led to a signiﬁcant increase in prolactin
secretion, indicating postsynaptic DA receptor D2 blockade,37,38 as
reported previously.24 Further, we did not observe any signiﬁcant
effects of sulpiride on blood pressure, heart rate or self-reported
measures of sedation.24
Previous studies observed that lower doses (that is, ⩽ 400 mg)
of sulpiride-induced impairments in tasks assessing SWM using
challenging tasks such as sequence generation,7 and the CANTAB
short-term spatial recognition/location task.23 In contrast, lower
doses of sulpiride did not induce impairments in tasks that are less
challenging, such as the verbal working memory task19 or the
easier (with a maximum of eight boxes) version of the CANTAB
self-ordered SWM task.43 Therefore, although this categorization
falls short of taking into account other differences than difﬁculty, it
is noteworthy that we observed impairments after a high single
dose of sulpiride-induced impairments speciﬁcally in the difﬁcult
(10- and 12-box), but not the easier problems of the CANTAB SWM
task. Our ﬁndings therefore extend on previous results and
suggest that effects may not be dose-dependent, but largely
depend on task difﬁculty.
Performance on the SWM task can be facilitated by using a
repetitive search strategy that serves to reduce the direct working
memory load. This strategy utilization recruits the prefrontal
cortex, as documented by imaging research as well as by a study
in frontal lobe lesion patients who seem to use a relatively
inefﬁcient search strategy.36,44 The fact that we found no
signiﬁcant effect of this high single dose of sulpiride on the
strategy measure suggests that our observed impairments are
unrelated to any potential impairment in prefrontal function.
Rather, striatal mediation is plausible, especially given that our
ﬁndings resemble those found in early stage Parkinson’s disease
patients, who do not show a deﬁcit in the strategy measure
either.45
Previous studies that used within-subject designs have reported
signiﬁcant interaction effects of sulpiride with administration
sequence.7,18 For instance, volunteers receiving sulpiride on the
ﬁrst day were impaired in SWM, but this was reversed in the
second testing session, that is, volunteers performed better on
sulpiride.7 Hence, although these previous ﬁndings raise interest-
ing questions with regards to a potential role of sulpiride in
learning or consolidation processes,7 they are difﬁcult to interpret.
Our ﬁndings that were obtained using a between-subjects design
provide more conclusive evidence for a role of DA D2 receptor
blockade in SWM.
With respect to planning, one study8 showed an improvement
in planning ability and another study7 reported a decrease in
planning ability after sulpiride administration. The latter study
found this decrease in planning ability only in the most difﬁcult
problems.7 At the higher dose of sulpiride used here, we observed
a planning impairment on both easier and more difﬁcult
problems. This divergence from earlier results could reﬂect a
genuine dosage effect: a high single dose of sulpiride is necessary
to achieve planning impairments on easier problems. However,
we cannot yet deﬁnitely conclude this, given that the earlier
study7 used a within-subject design, whereas we applied a
between-subject design, the results are not strictly comparable
and the differences in our results could potentially be caused by
these differences in the designs applied.
Planning latencies on the OTSOC clearly increased with problem
difﬁculty. In the most difﬁcult problems, latencies also correlated
negatively with accuracy, that is, volunteers with shorter response
Figure 4. Sulpiride (800 mg) effects on the relationship between
response latency and accuracy. (a) In this ﬁgure, the relationship is
shown for the easy problems (level 1–4). (b) In this ﬁgure, the
relationship is shown for the hardest problem (level 6). We have
added a ﬁtted line to illustrate the strength of the relationship.
OTSOC, one-touch stockings of Cambridge.
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latencies made more mistakes, consistent with a speed-accuracy
trade-off. Intriguingly, this relationship was more pronounced in
the sulpiride group. In a study using a version of a task similar to
the OTSOC that also requires planning of the solution in
advance,11 the times taken to correctly solve the more difﬁcult
problems were almost twice as long compared with those
observed in the original Tower of London task.46 This difference
can be explained by the additional increase of working memory
load in the OTSOC task compared with the original Tower of
London task.11 Given that sulpiride affected working memory in
our study too, the faster response latencies for difﬁcult problems
among the sulpiride group might suggest that excessive task
demands caused volunteers to guess impulsively on the most
difﬁcult problems.
In our previous study on the role of the DA receptor D2 in
reinforcement learning in the same cohort as the present study,24
a single dose of 800 mg of sulpiride had no effect on learning
per se, but rather induced profound impairments in choice
performance. These results were generally consistent with an
involvement of the DA receptor D2 in tonic dopaminergic activity
that has been linked to response vigour and motivational
effects.47 Although in the present study there were no monetary
rewards contingent on performance, impairments in motivation
may partially explain the effects we observed, particularly those in
the difﬁcult problems. Furthermore, unlike in our earlier study
where we found a modulatory role of the DA receptor D2 Taq1A
polymorphism on rewarded choice performance,24 here we found
no such differentiation of the sulpiride effect on planning ability or
SWM. Such a pharmacogenetic interaction effect would have been
the strongest evidence for a causal role of DA D2 receptors in
these executive functions. Sulpiride, despite being one of the few
relatively selective drugs affecting dopaminergic neurotransmis-
sion available for human use, has a very similar afﬁnity for the DA
D3 receptor as for the D2 receptor.48,49 Therefore, our results
indicate that the observed main effect of sulpiride on executive
functions may also partially be mediated by DA D3 receptors. In
this regard, it is interesting to note that preclinical research using
D3 receptor antagonists in animals suggests a rather distinct
proﬁle compared with D2 receptor antagonists by showing
positive effects on cognition.50 Alternatively, our ﬁndings might
also echo the greater functional blockade of cortical D2/3
receptors proposed for amisulpride,21 compared with striatal
receptor blockade.
With regards to our observed main effects of the DA receptor
D2 Taq1A polymorphism, it is noteworthy that previous beha-
vioural genetic studies have reported that the minor A1 allele (A1
+) is associated with poorer performance in general cognitive
ability,51 including visual working memory52 and verbal learning.53
A recent study54 that included the OTSOC as part of a larger test
battery found no effect of the presence of the A1+ allele on
planning. Thus, our ﬁndings are in line with those studies, showing
that the presence of the A1+ allele is associated with impairments
in SWM performance, but not with impairments in planning.
Although speculative, our results might therefore suggest that
while a high single dose of sulpiride is required to block a
sufﬁcient number of postsynaptic DA D2 receptors to produce
unambiguous deﬁcits in planning performance, this is not the case
with regards to spatial working memory performance. In the latter,
both lower7,23 and higher doses of sulpiride cause impairments in
difﬁcult problems suggesting that relatively low postsynaptic DA
D2 receptor occupancy levels sufﬁce to produce these impair-
ments. The fact that these impairments are also observed in A1+
allele carriers, irrespective of sulpiride administration, further
suggests that a ceiling-type of effect might exist, after which a
higher number of DA D2 receptor occupancy does not lead to a
more pronounced impairment in SWM. Whether DA D3 receptors
represent the neuropharmacological substrate of high single dose
sulpiride effects on planning performance, which would be
consistent with the absence of effects of the DRD2 Taq 1a
polymorphism in this and a previous study, is a subject for future
pharmacogenetic studies using larger sample sizes.
In sum, we observed that a high single dose of sulpiride induces
signiﬁcant impairments in planning accuracy and SWM. With
regards to SWM, this effect is dependent on task difﬁculty level.
Figure 5. The effects of the dopamine (DA) receptor D2 Taq1A genotype on the mean number of moves required to correctly solve the task
(accuracy) (a and b) and the mean log response latency taken for the ﬁrst response to be made against task difﬁculty level (c and d) in the
OTSOC task. The left column (a and c) shows theses effects for the placebo group and the right column (b and d) for the sulpiride group only.
Plotted are means± error bars of two standard errors (corrected for repeated observations). OTSOC, one-touch stockings of Cambridge.
DA D2 receptor and human planning and memory
M Naef et al
6
Translational Psychiatry (2017), 1 – 8
We also found that sulpiride, even when given at a high single
dose, did not modulate the extent of the use of an inefﬁcient
strategy in the SWM task. However, it is unlikely that the effects of
sulpiride are attributable simply to impaired sensorimotor
processing, as effects in latencies varied with the level of cognitive
difﬁculty of the tasks. Sulpiride administration speeded response
latencies in the OTSOC on the most difﬁcult problems, which
might suggest that sulpiride increased impulsive guessing. Finally,
we found that the presence of the A1+ allele is associated with
impairments in SWM performance, but not with impairments in
planning. The lack of both a main effect of the DA receptor D2
Taq1A polymorphism and an interaction with sulpiride adminis-
tration on planning performance might suggest that sulpiride
exerts its impact on this cognitive measure via DA D3 receptors;
however, future pharmacogenetic studies using larger sample
sizes need to conﬁrm this.
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